Anticipate Dispensing Post-Exposure Prophylaxis for COVID-19
You'll hear buzz about casirivimab/imdevimab (Regen-COV), the first med authorized to PREVENT COVID-19 after exposure.
This monoclonal antibody is already authorized to TREAT certain outpatients 12 or older with COVID-19 who are at high risk for severe illness...such as those with diabetes, obesity, etc.
Now it may be used for COVID-19 prevention if these same high-risk patients are exposed to the virus...as "post-exposure prophylaxis."
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote